Literature DB >> 15118573

Side effects of medical therapy for chronic hepatitis C.

Mitchell L Shiffman1.   

Abstract

The treatment of chronic hepatitis C virus (HCV) has improved greatly over the past decade. Over half of all patients treated with the combination of peginterferon and ribavirin have the opportunity to achieve sustained virologic response. The major factors which interfere with this goal are the side effects of therapy which require that the doses of peginterferon or ribavirin be reduced or that these medications be discontinued. While some of these side effects can be overcome and treatment continued, some side effects are severe and potentially life threatening. Appropriate recognition and management of these side effects will both improve response to therapy and avoid unnecessary morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118573

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  10 in total

1.  The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Authors:  Tarek Hassanein; Mitchell L Shiffman; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

2.  Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.

Authors:  Cecilia T Costiniuk; Edward Mills; Curtis L Cooper
Journal:  Can J Gastroenterol       Date:  2008-04       Impact factor: 3.522

Review 3.  Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.

Authors:  Mitchell L Shiffman
Journal:  Curr Gastroenterol Rep       Date:  2006-02

4.  Pityriasis rosea associated with pegylated interferon alfa and ribavirin treatment in a patient with chronic hepatitis C.

Authors:  Rahmet Güner; Siran Keske; Imran Hasanoğlu; Mehmet Taşyaran
Journal:  Balkan Med J       Date:  2013-06-01       Impact factor: 2.021

5.  Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.

Authors:  Corrine E Munoz-Plaza; Shiela Strauss; Janetta Astone-Twerell; Don Des Jarlais; Marya Gwadz; Holly Hagan; Andrew Osborne; Andrew Rosenblum
Journal:  Int J Drug Policy       Date:  2007-08-06

6.  Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C.

Authors:  Jianjun Wang; Shaojie Xin; Xueyuan Jin; Yongqian Cheng; Tao Yan; Song Qing; Ning Ding; Ping Zhao
Journal:  Med Sci Monit       Date:  2016-05-30

Review 7.  Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications.

Authors:  Ioannis P Trougakos; Kimon Stamatelopoulos; Evangelos Terpos; Ourania E Tsitsilonis; Evmorfia Aivalioti; Dimitrios Paraskevis; Efstathios Kastritis; George N Pavlakis; Meletios A Dimopoulos
Journal:  J Biomed Sci       Date:  2021-01-12       Impact factor: 8.410

8.  A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients.

Authors:  Muhammad Idrees; Sheikh Riazuddin
Journal:  BMC Gastroenterol       Date:  2009-01-20       Impact factor: 3.067

9.  Engagement in the Hepatitis C care continuum among people who use drugs.

Authors:  Babak Tofighi; Joshua D Lee; Selena S Sindhu; Chemi Chemi; Noelle R Leonard
Journal:  J Subst Use       Date:  2020-01-01

10.  Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C.

Authors:  Dorta Guridi Zaily; Castellanos Fernandez Marlen; Dueñas-Carrera Santiago; Martínez Donato Gillian; Valenzuela Silva Carmen; Cinza Estevez Zurina; Arús Soler Enrique R; Alvarez-Lajonchere Liz; González Fabián Lisset; Lazo Del Vallín Sacha; Ferrer Bataille Elena
Journal:  Curr Ther Res Clin Exp       Date:  2017-04-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.